The Dominance of Ophthalmology in Anti-VEGF Applications
Ophthalmology stands as the largest application segment within the Anti-VEGF Market, revolutionizing the treatment of conditions that were once leading causes of blindness. Anti-VEGF drugs are the standard of care for wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). These conditions are caused by the abnormal growth of fragile, leaky blood vessels in the retina, which can lead to swelling and irreversible vision loss. By injecting anti-VEGF therapies directly into the eye, doctors can effectively halt this process, often preserving and sometimes even improving a patient's vision.
The increasing global prevalence of these eye conditions, particularly in the aging population and the growing number of people with diabetes, is a primary driver for this market segment. While the high cost and frequent administration of these treatments via injections can be a challenge, the significant clinical benefits they provide have made them indispensable. This has also spurred extensive research into developing new drug formulations and delivery systems that offer longer-lasting effects, aiming to reduce the treatment burden on patients and healthcare providers.